Posted by Michael Wonder on 03 Jul 2023
Celltrion applies for approval in US for eye treatment biosimilar
30 June 2023 - The biopharmaceutical company now covers ophthalmology as well as auto-immune disease and cancer medicine.
Celltrion on Friday said it applied for approval from the US FDA for CT-P42, a biosimilar of the eye treatment Eylea.
